Biophan Announces Investor Conference Call at 12:00 PM Eastern Today
Business Wire - May 18, 2004 08:02
President to Discuss Development of Breakthrough Long-Life Biothermal Battery and Other Proprietary Technologies
ROCHESTER, N.Y., May 18, 2004 (BUSINESS WIRE) -- Biophan Technologies, Inc. (OTCBB: BIPH), a leading developer of next generation biomedical technology, announced today that it will host an investor conference call today at 12:00 pm Eastern to discuss its acquisition of a majority interest in TE-Bio, LLC, a company developing a breakthrough, long-life power source for use in implanted medical devices, such as pacemakers, defibrillators, neurostimulators and drug pumps.
The Company will discuss the impact and market opportunity represented by this breakthrough technology. Following the discussion, Michael Weiner, CEO of Biophan, and other members of the executive management team will be available to answer questions regarding this and other technology which the Company is currently developing. Participants may ask questions during the Q & A segment of the call or, if they prefer, may e-mail questions in advance of the call to Randy Lewis, senior vice president of Trilogy Capital Partners, firstname.lastname@example.org. To access the call, Investors should call 888.423.3274, or from an international location by calling 651.291.0278. Please request the " Biophan Conference." Following the call, a replay will be available for thirty days by calling 800.475.6701, or internationally, at 320.365.3844, access code: 731878.
The technology is based on a patented innovation in the utilization of thermoelectric materials, using nanoscale-based, thin-film materials to convert thermal energy produced naturally by the human body into electrical energy. The resulting power can be used to " trickle charge" batteries for medium-power devices such as defibrillators, or directly power low-energy devices like pacemakers. The Company will be displaying the technology to over 6,000 healthcare professionals at the NASPE - Heart Rhythm Society`s Heart Rhythm 2004 Conference, May 19-22, 2004 in San Francisco, CA.
TE-Bio is developing an implantable power system that has the potential to provide as much as a 30-year life -- a five-fold increase in service life compared to existing technology. The technology is anticipated to dramatically extend the service life of neurostimulators and drug pumps that are used for treatment of tremors, diabetes, and chronic pain. Furthermore, since these devices can be implanted in young patients, the combination of TE-Bio technology and extended device life may reduce the number of replacement implants needed throughout a patient`s life.
About Biophan Technologies
Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have nine issued U.S. patents and over fifty patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, and photonics. Biophan`s technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com.
TE-Bio holds an exclusive license to a patented innovation for generating power for an implantable medical device using thermoelectric materials. The technology is applicable to a wide variety of devices from biosensors to cardioverter defibrillators. TE-Bio is a limited liability company owned 51% by Biophan Technologies, Inc., and 49% by Biomed Solutions, LLC. The company is developing the thermoelectric materials and related circuits, and will provide these devices to biomedical device manufacturers and battery companies on an OEM basis.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan`s MRI technologies; the approval of Biophan`s patent applications; the successful implementation of Biophan`s research and development programs; the acceptance by the market of Biophan`s products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan`s periodic filings with the Securities and Exchange Commission (the " SEC" ). As a result, this press release should be read in conjunction with Biophan`s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Biophan Technologies, Inc.
Biophan Technologies, Inc., Rochester
Carolyn Hotchkiss, 585/214-2407
or (Press Interviews)
Michael Weiner, 585/214-2441
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved